BioCentury | Aug 28, 2020
Product Development

Aug. 27 Quick Takes: Priority Review for casimersen in DMD, tepotinib in NSCLC; plus asciminib meets in CML and a farewell to digital pioneer Proteus

...13% and 8% of DMD patients, respectively.‘Real-time’ review for tepotinib in NSCLC FDA will review tepotinib...
...hydrocarbon receptorc-MET (MET; HGFR) - c-Met receptor tyrosine kinase BC Staff benvitimod, tapinarof (DMVT-505, GSK2894512, WBI-1001) Tepmetko (tepotinib, MSC2156119J) asciminib...
BioCentury | May 6, 2020
Regulation

FDA approval of Novartis’ capmatinib heralds arrival of new targeted lung cancer therapies

...is the first c-MET inhibitor for the patient subset to gain FDA approval, but Tempetko tepotinib...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

...Merck KGaA’s tepotinib for NSCLC Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved tepotinib...
...receptor tyrosine kinase LpxC - Bacterial UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase PDE-4 - Phosphodiesterase-4 Hongjiang Li, Staff Writer tepotinib (MSC2156119J) JZP-258 Pear...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

...and pralsetinib from Blueprint Medicines Co. are both designed for RET fusion-positive tumors; Merck KGaA’s tepotinib...
...KGaA reported an ORR of 50% across all treatment lines in c-Met positive patients for tepotinib...
...to file an NDA this year for capmatinib, and Merck is planning an NDA for tepotinib...
BioCentury | Jun 4, 2019
Clinical News

June 4 ASCO Quick Takes: Sarcoma data for Aadi's nab-sirolimus; plus c-MET inhibitor data for NSCLC

...tepotinib data Also reporting c-MET inhibitor data Monday at ASCO, Merck KGaA (Xetra:MRK) said tepotinib (MSC2156119J...
...registrational” trial, but did not disclose regulatory plans for tepotinib. Brian Moy, Assistant Editor capmatinib (INC280, incb28060) tepotinib (MSC2156119J) Aadi...
BioCentury | Jul 13, 2018
Clinical News

Merck KGaA reports response data for tepotinib in c-MET mutant NSCLC

...Merck KGaA (Xetra:MRK) said 500 mg once-daily tepotinib (MSC2167119J) led to a partial response rate of...
...therapy. Tepotinib is a small molecule c-MET inhibitor. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Tepotinib (MSC2156119J...
...safety, quality of life and pharmacokinetics Status: Updated Phase II data Milestone: NA Jaime De Leon tepotinib (MSC2156119J) American...
BioCentury | Jul 13, 2018
Clinical News

Merck KGaA's tepotinib meets in two Phase Ib/II trials for advanced HCC

...Merck KGaA (Xetra:MRK) said once-daily oral tepotinib (MSC2156119J) as first- and second-line treatment each met the...
...Tepotinib is a small molecule c-MET inhibitor. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Tepotinib (MSC2156119J...
...and biological response rate Status: Additional Phase Ib/II data Milestone: Additional data (2018) Jaime De Leon tepotinib (MSC2156119J) American...
BioCentury | Jun 16, 2018
Product Development

NSCLC disrupted

...enrolled patients who were anti-PD-1/PD-L1 naïve. Merck KGaA presented data from Phase II trials of tepotinib...
...metastatic NSCLC patients harboring c-MET exon 14-skipping mutations, who had received previous treatment with chemotherapy, tepotinib...
...in PD-1 naïve patients. Luciano Rossetti, head of global R&D at Merck KGaA, said the tepotinib...
BioCentury | Oct 20, 2017
Emerging Company Profile

One-upping c-MET

...’s Phase III candidate savolitinib and the Phase II compounds capmatinib from Novartis AG and tepotinib...
...Octimet is currently investigating whether the three competitors bind OCT2. Merck spokesperson Brenda Mulligan said tepotinib...
BioCentury | Jun 2, 2017
Clinical News

Merck reports Phase II data for c-MET inhibitor tepotinib in lung adenocarcinoma

...oral tepotinib (MSC2156119J) led to 2 unconfirmed partial responses and 1 case of stable disease. Tepotinib...
...pharmacokinetics. Tepotinib is a small molecule c-MET inhibitor. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Tepotinib (MSC2156119J...
...survival (OS), safety, quality of life (QOL) and pharmacokinetics Status: Phase II data Milestone: NA Julian Zhu MSC2156119J tepotinib American...
Items per page:
1 - 10 of 14